New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset
Executive Summary
Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.
You may also be interested in...
Intuitive Surgical Sees Procedure Volume Surge; Drug Competition Threatens Bariatric Business
The robotic surgery giant reported rapid procedure growth across all surgical division except bariatrics, worrying some investors.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.
Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.